<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02822131</url>
  </required_header>
  <id_info>
    <org_study_id>Phos-RR</org_study_id>
    <nct_id>NCT02822131</nct_id>
  </id_info>
  <brief_title>Phosphate in Blood Pressure Regulation</brief_title>
  <acronym>Phos-RR</acronym>
  <official_title>The Effect of Dietary Phosphate Intake on Blood Pressure Regulation and Renal Sodium Chloride Excretion in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      High dietary phosphate intake in the general population is associated with a higher risk for&#xD;
      developing kidney disease and cardiovascular disease with an increased overall mortality.&#xD;
      Whereas the effects of high phosphate intake on general health become clearer, almost nothing&#xD;
      is known about underlying mechanisms. More recently, the investigators and others found in&#xD;
      animal models that FGF23 stimulates the renal NaCl cotransporter NCC, the target of thiazide&#xD;
      diuretics, and that increased NCC activity may increase blood pressure. The investigators&#xD;
      could also show that increasing dietary phosphate intake in mice, increases FGF23 and NCC&#xD;
      activity within 3 days. Thus, the objective of this single-centre observational cross-over&#xD;
      study including 20-45 year old healthy male probands is to elucidate the role of dietary&#xD;
      phosphate on blood pressure regulation and renal handling of sodium chloride in healthy&#xD;
      subjects. Further the impact of dietary phosphate intake on the regulation of phosphaturic&#xD;
      hormones and other factors regulation blood pressure will be investigated. In addition, the&#xD;
      investigators will examine whether phosphate intake modulates gut microbiome composition. The&#xD;
      primary outcome in this study is the change in blood pressure in healthy subjects on&#xD;
      low-phosphate diet compared to healthy subjects on high-phosphate diet. In addition, to&#xD;
      assess changes in NCC activity as the main mechanism of phosphate-sensitive blood pressure&#xD;
      regulation, renal sodium chloride excretion after administration of hydrochlorothiazide will&#xD;
      be measured. The secondary outcomes of this study are: changes in renal phosphate, calcium&#xD;
      and potassium excretion, changes in phosphate regulation hormones such as 25-OH-Vit. D,&#xD;
      1,25-(OH)2-Vit. D, PTH, FGF23, dopamine in plasma and urine, changes in plasma and urinary&#xD;
      aldosterone levels, changes in sodium/chloride-cotransporter NCC and NaPi-IIa assessed from&#xD;
      urinary exosomes, and changes in stool phosphate excretion and gut microbiome composition.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in blood pressure</measure>
    <time_frame>5 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in renal sodium chloride excretion</measure>
    <time_frame>5 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>low phosphate</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>low phosphate will be induced by low phosphate diet and additional treatment with oral phosphate binder sevelamer.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>high phosphate</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>high phosphate diet will be induced by oral supplementation with sodium phosphate.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>sodium phosphate</intervention_name>
    <arm_group_label>high phosphate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sevelamer, sodium bicarbonate, sodium chloride</intervention_name>
    <arm_group_label>low phosphate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  20-45 year old healthy male subjects&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  - Kidney disease (defined by eGFR &lt; 90 ml/min or microalbuminuria (&gt; 30mg/d))&#xD;
&#xD;
          -  Diabetes mellitus&#xD;
&#xD;
          -  Hypertension (RR &gt; 140/85 mmHg)&#xD;
&#xD;
          -  Hypotension (RR &lt; 90/60 mmHg)&#xD;
&#xD;
          -  any regular medication&#xD;
&#xD;
          -  non-Western type diet e.g. vegetarian, vegan etc.&#xD;
&#xD;
          -  History of kidney stones&#xD;
&#xD;
          -  Allergy to sulphonamides or penicillins&#xD;
&#xD;
          -  Hereditary fructose intolerance&#xD;
&#xD;
          -  known hypersensitivity or allergy to class of drugs used in this study&#xD;
&#xD;
          -  Glaucoma&#xD;
&#xD;
          -  Vitamin D deficiency (&lt; 20 ng/ml)&#xD;
&#xD;
          -  Hyper- or Hypoparathyroidism&#xD;
&#xD;
          -  Hypo- or hyperaldosteronism&#xD;
&#xD;
          -  Participation in any other study&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Hospital Zurich, Nephrology</name>
      <address>
        <city>Zurich</city>
        <state>ZH</state>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <study_first_submitted>April 8, 2016</study_first_submitted>
  <study_first_submitted_qc>June 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2016</study_first_posted>
  <last_update_submitted>June 29, 2016</last_update_submitted>
  <last_update_submitted_qc>June 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Zurich</investigator_affiliation>
    <investigator_full_name>Nilufar Mohebbi</investigator_full_name>
    <investigator_title>PD Dr. med.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sevelamer</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

